Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy
- PMID: 18984781
- DOI: 10.1148/radiol.2493080226
Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy
Abstract
Purpose: To prospectively determine whether perfusion computed tomography (CT) parameters, such as volume transfer constant (K(trans)) between blood plasma and extracellular extravascular space (EES) and blood volume calculated from dynamic CT data, can be used to predict response of pancreatic cancer to concurrent chemotherapy and radiation therapy (CCRT).
Materials and methods: This prospective study was institutional review board approved, and written informed consent was obtained. Thirty patients with pancreatic cancer underwent perfusion CT with 64-detector row CT before gemcitabine-based CCRT. Two perfusion parameters (K(trans) and blood volume) measured before treatment were compared between patients who responded to treatment and those who did not, as determined with World Health Organization criteria from first and second posttherapeutic follow-up CT examinations, which were performed at 3- and 6-month follow-up. Statistical analysis was performed with the two-sample t test. A receiver operating characteristic curve was used to determine the best cutoff value of perfusion parameters for differentiation of responders from nonresponders.
Results: Twenty of 30 patients examined at 3-month follow-up responded to therapy. Their pretreatment K(trans) value was significantly higher than that of nonresponders (50.8 mL/100 mL/min +/- 30.5 [standard deviation] vs 19.0 mL/100 mL/min +/- 10.8, P = .001). The best cutoff value for differentiating between responders and nonresponders was 31.8 mL/100 mL/min, which yielded 75.0% sensitivity and 90.0% specificity. Ten of 18 patients examined at 6-month follow-up responded to therapy. Their pretreatment K(trans) value was significantly higher than that of nonresponders (58.6 mL/100 mL/min +/- 43.2 vs 19.8 mL/100 mL/min +/- 10.9, P = .002). Responders also had higher blood volume values, but this difference was not significant.
Conclusion: Tumors with a high pretreatment K(trans) value tended to respond better to CCRT than did tumors with a low pretreatment K(trans) value. Perfusion CT may be used to predict tumor response to CCRT in patients with pancreatic cancer. This might aid in development of a tailored approach to therapy in these patients.
(c) RSNA, 2008.
Similar articles
-
Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.Radiology. 2010 Aug;256(2):441-9. doi: 10.1148/radiol.10091733. Epub 2010 Jun 1. Radiology. 2010. PMID: 20515976 Clinical Trial.
-
Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma.Cardiovasc Intervent Radiol. 2007 Sep-Oct;30(5):912-21. doi: 10.1007/s00270-007-9134-2. Epub 2007 Aug 21. Cardiovasc Intervent Radiol. 2007. PMID: 17710478 Clinical Trial.
-
Quantitative dynamic contrast-enhanced MR imaging for the preliminary prediction of the response to gemcitabine-based chemotherapy in advanced pancreatic ductal carcinoma.Eur J Radiol. 2019 Dec;121:108734. doi: 10.1016/j.ejrad.2019.108734. Epub 2019 Nov 6. Eur J Radiol. 2019. PMID: 31743881
-
Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations.Radiology. 2005 Mar;234(3):785-92. doi: 10.1148/radiol.2343040286. Radiology. 2005. PMID: 15734934
-
Response and progression-free survival in oropharynx squamous cell carcinoma assessed by pretreatment perfusion CT: comparison with tumor volume measurements.AJNR Am J Neuroradiol. 2009 Apr;30(4):793-9. doi: 10.3174/ajnr.A1449. AJNR Am J Neuroradiol. 2009. PMID: 19351906 Free PMC article. Clinical Trial.
Cited by
-
Automated Quantitative Analysis of CT Perfusion to Classify Vascular Phenotypes of Pancreatic Ductal Adenocarcinoma.Cancers (Basel). 2024 Jan 30;16(3):577. doi: 10.3390/cancers16030577. Cancers (Basel). 2024. PMID: 38339328 Free PMC article.
-
Dual-energy computed tomography-based iodine concentration as a predictor of histopathological response to preoperative chemoradiotherapy for pancreatic cancer.J Radiat Res. 2023 Nov 21;64(6):940-947. doi: 10.1093/jrr/rrad076. J Radiat Res. 2023. PMID: 37839063 Free PMC article.
-
Decrease in Pancreatic Perfusion of Patients with Type 2 Diabetes Mellitus Detected by Perfusion Computed Tomography.J Clin Imaging Sci. 2021 Sep 27;11:50. doi: 10.25259/JCIS_72_2021. eCollection 2021. J Clin Imaging Sci. 2021. PMID: 35003832 Free PMC article.
-
Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine.Diagnostics (Basel). 2021 Nov 22;11(11):2166. doi: 10.3390/diagnostics11112166. Diagnostics (Basel). 2021. PMID: 34829513 Free PMC article. Review.
-
Improving radiation physics, tumor visualisation, and treatment quantification in radiotherapy with spectral or dual-energy CT.J Appl Clin Med Phys. 2022 Jan;23(1):e13468. doi: 10.1002/acm2.13468. Epub 2021 Nov 7. J Appl Clin Med Phys. 2022. PMID: 34743405 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical